We provide a clinically useful, reliable, comprehensive, up-to-date, evidence-based drug-drug interaction resource, freely available to healthcare workers, patients and researchers.
Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.
We strongly believe that drug information should be offered free of charge, be independent, and be evidence-based and transparent. We are convinced that quality of care is vitally important: by providing a world-leading DDI resource which improves DDI education and promotes safer prescribing, we aim to improve the quality of care for cancer patients worldwide.
Information presented relates only to known or suspected effects of interacting medications, and is based on relevant data in the public domain. No clinical advice is given or implied, clinicians must exercise their own judgement in relation to the risks and benefits of combining drugs, which depend on factors beyond pharmacokinetic interactions between two drugs. Neither the University of Liverpool nor any of the listed sponsors, shall be held responsible for the application or use of any information it gives and the user shall hold the University of Liverpool and sponsors harmless against any consequences arising from the same.